Drive Efficiency with Hematology Prior Authorization Automation

Klivira delivers comprehensive hematology prior authorization automation, transforming complex workflows for high-cost therapies and specialized diagnostics into efficient, compliant processes.

Managing prior authorizations in hematology presents unique challenges due to the high cost of specialty drugs like factor concentrates and CAR-T cell therapies, alongside intricate documentation requirements. Revenue cycle directors and prior authorization coordinators face increasing pressure to reduce denial rates and accelerate patient access to critical treatments for conditions ranging from hemophilia to hematologic malignancies.

The Unique Landscape of Hematology Prior Authorizations

Hematology encompasses a diverse range of conditions, from inherited bleeding disorders to complex hematologic malignancies. Prior authorization requirements are particularly stringent for high-cost therapies such as factor concentrates, novel sickle cell disease therapeutics, and advanced CAR-T cell therapies, which often trigger extensive documentation and review processes. This complexity necessitates a specialized approach to PA management.

High-Volume Prior Authorization Categories in Hematology

  • Hematologic Oncology: Biologics and chemotherapies for lymphomas, leukemias, multiple myeloma, including CAR-T cell therapies (Yescarta, Kymriah, Breyanzi, Tecartus, Carvykti, Abecma) [corpus].
  • Hemophilia Factor Concentrates: Factor VIII and IX products (Advate, Adynovate, Hemlibra, BeneFIX, Alprolix, Rebinyn, Idelvion) for prophylaxis and on-demand treatment [corpus].
  • Sickle Cell Disease Therapeutics: Specialty drugs such as voxelotor (Oxbryta), crizanlizumab (Adakveo), and emerging gene therapies (Casgevy, Lyfgenia) for SCD [corpus].
  • VTE/Anticoagulation Specialty Drugs: Direct Oral Anticoagulants (DOACs) in specific, often complex, clinical scenarios [corpus].
  • Bone Marrow / Stem Cell Transplant: Autologous and allogeneic transplant procedures and associated services [corpus].

Navigating Complex Documentation and Clinical Guidelines

Hematology prior authorizations demand meticulous documentation, often aligned with specific clinical practice guidelines. Klivira's platform incorporates ASH guidelines (src: ash-guidelines) and NCCN guidelines for hematologic oncology (src: nccn-guidelines), streamlining the collection of essential data points like factor levels for hemophilia and prior-line therapy documentation for CAR-T cell therapies [corpus].

Addressing Common Prior Authorization Denial Reasons

Denials in hematology frequently stem from specific issues, including gaps in NCCN compendium alignment for novel agents, discrepancies in hemophilia factor prophylaxis versus on-demand criteria, and incomplete CAR-T eligibility documentation [corpus]. Klivira's intelligent workflows are designed to proactively identify and mitigate these common denial triggers.

Klivira's Solution for Hematology Prior Authorization Automation

Klivira's platform provides specialized capabilities for hematology prior authorization automation, integrating ASH/NCCN-aware policy logic and specific workflows for complex cases. Our system automates hemophilia factor utilization tracking, streamlines CAR-T eligibility documentation, and manages intricate transplant PA workflows, ensuring comprehensive support for your hematology practice [corpus].

Seamless Integration with Your Existing EMR

Klivira integrates with your existing Electronic Medical Record (EMR) system to pull necessary patient data, reducing manual data entry and improving accuracy. This ensures that clinical documentation, such as factor levels or prior-line therapies, is automatically leveraged for prior authorization submissions, minimizing administrative burden for your hematology team.

Frequently asked questions

How does Klivira handle the specific documentation for hemophilia factor concentrates?

Klivira's system is designed to track hemophilia factor utilization and prompt for essential documentation such as factor levels, joint health status, and bleeding episode tracking, aligning with payer requirements for prophylaxis versus on-demand treatment [corpus].

Can Klivira assist with prior authorizations for CAR-T cell therapies?

Yes, Klivira automates CAR-T eligibility documentation by integrating NCCN guidelines and ensuring all necessary data, including diagnosis confirmation and prior-line therapy details, is captured for submission, addressing common denial reasons related to eligibility [corpus].

How does Klivira stay updated with evolving clinical guidelines like ASH and NCCN?

Klivira's platform incorporates ASH guidelines (src: ash-guidelines) and NCCN guidelines (src: nccn-guidelines) into its policy logic. Our system is regularly updated to reflect changes in these critical clinical standards, helping ensure compliance with current payer medical policies.

What types of sickle cell disease treatments does Klivira support for prior authorization?

Klivira supports prior authorizations for a range of sickle cell disease therapeutics, including specialty drugs like voxelotor (Oxbryta) and crizanlizumab (Adakveo), as well as emerging gene therapies such as Casgevy and Lyfgenia [corpus].

Does Klivira integrate with payer portals for hematology-specific submissions?

Klivira automates prior authorization submissions across various channels, including direct EMR integrations, X12 278 transactions, and payer portal automation. This comprehensive approach ensures that hematology PAs are submitted through the required channels for each payer.

Related coverage

Drive prior auth workflows

Drive prior auth coverage by state

Drive prior authorization by drug

Drive prior authorization by procedure

Ready to automate prior auth for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo